A 100% effective cancer vaccine? Russia’s Enteromix achieves success in trials; Here’s the full report you need to read

A vaccine that could change the way we fight cancer is making headlines. Russia’s Enteromix has reportedly achieved 100% efficacy in preclinical trials, showing both safety and strong tumour-fighting abilities, according to a report by Tass.

Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA), revealed the results at the Eastern Economic Forum (EEF).

“The research spanned several years, with the last three dedicated to mandatory preclinical studies. The vaccine is now ready for use; we are awaiting official approval,” Tass quoted her as saying.

Skvortsova stressed that repeated administration of the vaccine remained safe, while also showing impressive results. Tumour growth slowed by 60–80%, survival rates improved, and significant reductions in tumour size were observed.

First target: colorectal cancer

The vaccine’s initial focus will be on colorectal cancer, a leading cause of cancer-related deaths worldwide. But the research does not stop there. Scientists are also developing versions for glioblastoma, a highly aggressive brain tumour, and specific types of melanoma, including ocular melanoma, all of which are at advanced stages of study.

Most of us associate vaccines with childhood diseases such as measles or chickenpox. These train the immune system to recognise dangerous germs. Cancer vaccines work on a similar principle, but instead of viruses, they help the body spot and attack cancer cells.

According to the American Cancer Society, some cancer vaccines already exist for bladder and prostate cancers, while the HPV vaccine prevents several types of cancer before they begin. Enteromix, however, belongs to a growing line of therapeutic vaccines designed to treat cancer directly, making the body’s natural defences more powerful.

Global stage for a breakthrough

The announcement came during the 10th Eastern Economic Forum in Vladivostok (3–6 September), where over 8,400 delegates from 75 countries gathered under the theme “The Far East: Cooperation for Peace and Prosperity.” More than 100 thematic sessions were held, but it was Enteromix that stole the spotlight.

If approved, this Russian vaccine could be a milestone in the fight against one of the world’s deadliest diseases, potentially reshaping cancer treatment as we know it.

Inputs from ANI